The aim of the present study was to investigate ,3-adrenergic receptor and angiotensin II (Ang II) receptor modulation of norepinephrine release in human atria. Slices of human atrial appendages were incubated with ['H]norepinephrine, superfused with Krebs-Henseleit solution, and electrically stimulated in superfusion chambers. Pretreatment of the tissue with 6-hydroxydopamine (1.2 mmol/L) before the ['H]norepinephrine incubation to destroy sympathetic nerves reduced the uptake of radioactivity and abolished the stimulation-induced (S-I) outflow of radioactivity. Furthermore, S-I outflow of radioactivity was prevented by the addition of tetrodotoxin (1 ,xmol/L) to and omission of extracellular Ca 2+ from the superfusion solution. Separation of ['H]norepinephrine from its metabolites revealed that the S-I outflow of radioactivity was mainly composed of intact ['H]norepinephrine. Thus, the S-I outflow of radioactivity was taken as an index of norepinephrine release. Isoproterenol (0.001 to 0.1 ,umol/L) dose-dependently enhanced the S-I outflow of radioactivity. The concentration-response curve of isoproterenol was shifted to the right by the selective 832-adrenergic receptor antagonist ICI 118551 (0.01 and 0.1 j.tmol/L) but not by the 3,1-adrenergic receptor-selective antagonist atenolol (0.3 and 30 ,umol/L). Ang 11 (0.001 to 1.0 /kmol/L) also dose-depen-S ympathetic nerve terminals of various tissues possess prejunctionally located receptor systems that, when activated, enhance or inhibit the amount of norepinephrine released per nerve impulse.'-4One of these prejunctional facilitatory receptor systems is mediated via ,B-adrenergic receptors.5.6 ,B-Adrenergic receptors can be divided in f, and 2 subtypes,7 and it is generally believed that prejunctional ,B-adren-
ergic receptors are of the 12 subtype. Most of the studies regarding prejunctional ,3-adrenergic receptor function have been performed in isolated sympathetically innervated tissues of various animal species.5 -7 Regarding cardiac sympathetic nerves, it has been shown that activation of prejunctional ,B-adrenergic receptors facilitates norepinephrine release in isolated atria of guinea pigs,8.9 rats,10 and mice." There is now a substantial body of evidence that the human heart possesses both A13and 8,2-adrenergic receptors; however, most functional studies have focused on the role of fi-adrenergic tatsklinik Freiburg, Hugstetter Str 55, D-79106 Freiburg, Germany. dently enhanced S-I outflow of radioactivity. The facilitatory effect of Ang II was blocked by either the peptide Ang II receptor antagonist saralasin (1.0 pmol/L) or EXP 3174 (0.1 ,umol/L), the in vitro active form of the nonpeptide Ang II receptor antagonist losartan. The cell-permeable cAMP analogue 8-bromo-cAMP (30 to 300 ,umol/L) dose-dependently enhanced S-I outflow of radioactivity. A combination of a saturating concentration of 8-bromo-cAMP (300 ,umol/L), the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 90 ,umol/L), and isoproterenol (0.1 ,umol/L) did not enhance S-I outflow of radioactivity to a greater extent than did isoproterenol (0.1 ,tmol/L) alone. In contrast, a combination of 8-bromo-cAMP (300 ,umol/L), IBMX (90 gmol/L), and Ang 11 (0.1 ,mol/L) enhanced S-I outflow of radioactivity to a greater extent than did Ang 11 (0.1 ,umol/L) alone. The data suggest that norepinephrine release from sympathetic nerves in human atria is facilitated through prejunctional f2-adrenergic receptors and Ang II receptors. Prejunctional ,2-adrenergic receptors but not Ang II receptors seem to be linked to activation of an adenylate cyclase pathway. (Circ Res. 1994 ;74:434-440.) Key Words * /2-adrenergic receptors * angiotensin II receptors * norepinephrine * human atria receptors on myocardial12 13and sinoatrial" pacemaker cells. Little systematic work has been done regarding prejunctional receptor function in the human heart.15'16 Another prejunctional facilitatory system is mediated by angiotensin II (Ang II) receptors.'-4,17 Accordingly, it has been shown that Ang II enhances norepinephrine release in guinea pig,'8 mouse,'9 and rat20 isolated atria, but no data are available regarding a direct prejunctional effect of Ang II in human cardiac tissue. Therefore, the aim of the present study was (1) to establish a reliable technique that permits investigation of the modulation of norepinephrine release from sympathetic nerves in human atria and (2) to characterize the modulatory effects of 1-adrenergic receptor and Ang II receptor activation.
Materials and Methods

Human Right Atrium
The present in vitro study in human right atrial appendages was approved by the local ethics committee. The majority of right atrial appendages was taken from 57 patients (33 to 77 years of age; mean age, 60.3 + 1.2 years) undergoing open heart surgery for coronary bypass grafting with no signs of heart failure. Four patients were classified according to the New York Heart Association (NYHA) as NYHA II to III. None of the patients had been treated with drugs known to interact with either the storage or release mechanism of norepineph-rine. Four patients had received 13-adrenergic receptor-blocking drugs, and three patients had received angiotensin-converting enzyme inhibitors. The right atrial appendages were cleared from all connective tissue, and slices (z~0.3 mm thick; diameter, 6.0 mm) were prepared.
Experimental Design
The slices were incubated with (-)-[2,5,6,-3Hlnorepinephrine (42.1 Ci/mmol, 0.5 ,umol/L) for 60 minutes in Krebs-Henseleit solution that was continuously bubbled with carbogen (95% 02-5% C02). The slices were then placed into six superfusion chambers (volume, 250 gL) between two platinum electrodes and were kept in a bath at a temperature of 37°C as previously described for human renal cortex.2' The slices were superfused at a constant rate of 2.5 mL/min with Krebs-Henseleit solution for 141 minutes to remove loosely bound radioactivity. After 120 minutes of this washing procedure, a priming stimulation (10 Hz, 38-mA current strength, 1-millisecond pulse width, for 1 minute) was given, and cocaine (10 gumol/L) was added to the superfusion solution. Then, after the washing, consecutive samples of the superfusate were collected in 3-minute fractions with a fraction collector (Isco Retriever IV, Isco, Lincoln, Neb). There were four stimulation periods (S to S4, 27 minutes apart, 38 mA, 10 Hz for 1 minute). A few experiments were performed with only two electrical stimulations (S, and S2). S, always served as a reference stimulation. The effect of drugs was tested by adding them in increasing concentrations to the superfusion solution 12 minutes before S2, S3, and S4. In those experiments in which a drug was present for both stimulation periods (throughout), it was added to the superfusion solution immediately after the priming stimulation. In some experiments, the superfusate samples were tested for their [3Hjnorepinephrine content by sequential alumina and Dowex column chromatography.22
Estimation of Radioactivity
The collected 3-minute samples of the superfusion solution were mixed with 8 mL scintillation fluid (Picofluor 40, Packard Instruments, Downers Grove, Ill) to measure the amount of radioactivity present in the superfusion solution by liquid scintillation counting. Total tissue radioactivity was determined at the end of each experiment. The atrial slices were dissolved in 1 mL tissue solubilizer (Soluene, Packard Instruments) and then mixed with 8 mL scintillation fluid.
Calculation of Results
The spontaneous outflow of radioactivity from the slices was determined as the mean of the amount of radioactivity in the superfusate collected during the 3-minute collection period immediately before and 12 minutes after the onset of stimulations (S5 to S4). The stimulation-induced (S-I) outflow of radioactivity was calculated by subtracting the spontaneous outflow of radioactivity from the radioactivity present in the four 3-minute samples collected immediately after the onset of stimulation. The S-I outflow of radioactivity is subsequently expressed as a fraction (percentage) of the total tissue content of radioactivity at the time of stimulation (fractional S-I outflow of radioactivity [FR]). S, (FR,) served as a reference stimulation, and the fractional S-I outflow of radioactivity in S. (FR2 to FR4) is expressed as a percentage of that in S, (FRn as a percentage of FR,). The spontaneous (resting) outflow of radioactivity during S,, is expressed as a percentage of that during S, (Rn as a percentage of R,). For further evaluation of drug effects, the FRn/FR, values were calculated as a percentage of the values in the corresponding control experiments.
The pKB value for ICI 118551 was calculated according to Equation 4 of Furchgott.23 All data are expressed as mean±SEM. Multiple slices were prepared from each atrium, so that different treatments could be tested in one atrium; n gives the number of atria used in each group. Data were ANOVA where appropriate. Values of P< .05 were considered statistically significant.
6-Hydroxydopamine Pretreatment
Some experiments were performed in atrial slices that were pretreated with 6-hydroxydopamine (1.2 mmol/L) for 10 minutes before incubation with [3Hjnorepinephrine as previously described for rat caudal artery and portal vein24 and human kidney cortex.2' In this case, NaHCO3 and KH2PO4 were omitted from the Krebs-Henseleit solution. Glutathione was added to give a final concentration of 20 gmol/L. The pH of this solution was between 3.0 and 4.0. Vehicle control experiments were always run in parallel.
Determination of Tissue Levels of Endogenous Norepinephrine
Right atrial appendages were weighed and immediately placed into centrifugation tubes containing perchloric acid (0.1 ,umol/L). The atrial appendages were homogenized and then centrifuged at 10 000 rpm for 15 minutes at 4°C. The endogenous norepinephrine levels were measured in aliquots of the supernatant by high-pressure liquid chromatography coupled with electrochemical detection as described previously. 25 Frequency-Response Curve of the S-I
Outflow of Radioactivity
In some experiments, the influence of the stimulation frequency on the S-I outflow of radioactivity from human right atrial appendages preincubated with [3H]norepinephrine was tested. After the washing procedure, there were nine stimulation periods each for 1 minute, 38-mA current strength, 1-millisecond pulse width: S, (1.25 Hz), S2 (2.5 Hz), S3 (5 Hz), S4 (10 Hz), S5 (12.5 Hz), S6 (20 Hz), S7 (25 Hz), S8 (35 Hz), and S9 (50 Hz). The S-I outflow of radioactivity for each stimulation period was calculated as described above (calculation of data).
Drugs and Vehicles
The Krebs-Henseleit solution had the following composition (mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 0.45, NaHCO3 25, KH2PO4 1.03, D-(+)-glucose 11.1, disodium edetate 0.067, corticosterone 0.03, and ascorbic acid 0.07.
The following drugs were purchased: levo-[ring-2,5,6-3H]norepinephrine (NEN, Dreieich, Germany); 8-bromo-cAMP, (+)-isoproterenol hydrochloride, tetrodotoxin, corticosterone, 6-hydroxydopamine hydrobromide, tetrodotoxin, 3-isobutyl-1-methylxanthine (IBMX), and [Sarl,Val',Ala8I-Ang II (saralasin) (Sigma Chemical Co, St Louis, Mo); and cocaine hydrochloride (Merck, Darmstadt, Germany).
The following drugs were generously donated: erythro-DL-1- 
Results
Two hundred ten human right atrial appendage slices (mean wet weight, 9.7+0.3 mg) from 57 patients were incubated with [3H]norepinephrine and superfused with Krebs-Henseleit solution in superfusion chambers between two platinum electrodes. The slices accumulated radioactivity (228 000±10 600 dpm/mg). Tissue levels of endogenous norepinephrine were 2.4±0.38 gg/g (n=9). There were either two or four electrical field stimulations (S5 to S4) at 10 Hz for 1 
6-Hydroxydopamine on S-I Outflow of Radioactivity
In control experiments, S-I outflow of radioactivity was constant over four (S1 to S4) stimulation periods (Fig 1) . The sodium channel blocker tetrodotoxin (1 gLtmol/L), which was added to the superfusion solution 12 minutes before S2, and the omission of Ca2' abolished S-I outflow of radioactivity (not shown). In vitro pretreatment of the tissue with 6-hydroxydopamine (1.2 mmol/L) before incubation with [3H]norepinephrine reduced total tissue radioactivity and abolished S-I outflow of radioactivity (Fig 1) . Influence of the Stimulation Frequency on the S-I
Outflow of Radioactivity
Electrical stimulation from 1.25 to 50 Hz induced a frequency-dependent increase of the S-I outflow of radioactivity (Fig 2) . The maximum increase of the S-I outflow of radioactivity was reached at a frequency of 20 Hz. After incubation with [3H]norepinephrine, the slices were superfused with Krebs-Henseleit solution in superfusion chambers. Consecutive 3-minute fractions of the superfusate were collected. There were four stimulation periods (Sl to S4), each 27 minutes apart at 10 Hz for 60 seconds. Total tissue radioactivity was measured at the end of each experiment. The S-I outflow of radioactivity (S1 to S4) and the basal outflow of radioactivity are expressed as a fraction (percentage) of the total tissue radioactivity at the time of the collection (fractional S-I outflow). All data are mean+±SEM. Isoproterenol was added in increasing concentrations before S2 tO S4. Results are the ratios Sn/S1 (S2/S1, S3/S1, and S4/S1) expressed as a percentage of the ratios obtained in the corresponding control experiments. The effect of isoproterenol alone (A and B, ., n=10) and in the presence of 0.01 limol/L IC01118551 (A, ii, n =8) and in the presence of 0. 1 g.mol/L 10Cl1118551 (A, v, n =6) is shown. The effect of isoproterenol in the presence of 0.3 gmol/L atenolol (B3, D, n=6) and in the presence of 30 !Lmol/L atenolol (B3, v, n=6) is shown. All data are mean±SEM. *Significant effect of isoproterenol as compared with control experiment (P< .05 by modified t test according to Bonferroni). +Signfilcant effect of treatment with IC01118551 (P<.05 by ANOVA). Treatment with atenolol had no signifficant effect (P>.05 by ANOVA).
Effect of Isoproterenol on the S-I Outflow of Radioactivity
The I31-and /32-adrenergic receptor agonist isoproterenol (0.001 to 0.1 gmol/L) dose-dependently enhanced S-I outflow of radioactivity (Fig 3) . The concentration-response curve of isoproterenol was shifted to the right by the 832-adrenergic receptor-blocking drug ICI 118551 (0.01 g.mol/L) with an estimated pKB of 9.1 (Fig 3A) . In the presence of ICI 118551 (0.1 g.molIL), the facilitatory effect of isoproterenol (0.001 to 0.1 1£mol/L) was totally abolished (Fig 3A) . However,, the /31-adrenergic receptor-blocking drug atenolol (0.3 and 30 g.mol/L) failed to alter the facilitatory effect of isoproterenol (0.001 to 0.1 4ltmol/L) ( Fig 3B) . Isoproterenol (0.01 gtmol/L) Hz for 60 seconds). Angiotensin was added in increasing concentrations before S2 tO S4. Results are the ratios Sn/S1 (S2/S1, S3/S1, and S4/S1) expressed as a percentage of the ratios obtained in the corresponding control experiments. slightly increased the spontaneous outflow of radioactivity to 78.5±+0.7% (n=10) as compared with the control level of 75.4±+0.9% (n= 15), and isoproterenol (0.1 p.mol/L) slightly increased the spontaneous outflow of radioactivity to 74.8±+1.2% (n= 10) as compared with the control level of 69.6-±1.2% (n==15).
Effect of Ang on the S-I Outflow of Radioactivity
Ang 11 (0.001 to 0.1 g~mol/L) dose-dependently enhanced the S-I outflow of radioactivity (Fig 4) . The facilitatory effect of Ang was markedly attenuated by the Ang receptor antagonist saralasin (1 gimol/L) and totally abolished by EXP 3174 (0.1 gmol/L) (Fig 4) . Ang outflow of radioactivity to 77.9±1.2% (n=6) as compared with the control level of 74.7±1.0% (n= 12).
Effect of ICI 118551, Atenolol, Saralasin, and EXP 3174 on the S-I Outflow of Radioactivity
The effect of the antagonists by themselves was tested in experiments with only two stimulations (S, and S2), and the antagonists were always added 12 minutes before S2. As compared with the control level (90.8±2.9%, n=10), none of the following antagonists had a significant effect on the S-I outflow of radioactivity: ICI 118551 (0.1 ,mol/L, 85.6±4.8%, n=4), atenolol (0.3 gimol/L, 100.5±3.5%, n=5), saralasin (1 ,mol/L, 94.4±3.5%, n=4), and EXP 3174 (0.1 ,tmol/L, 95.7±4.7%, n=6). None of the drugs altered the spontaneous outflow of radioactivity (data not shown).
Effect of 8-Bromo-cAMP and Combinations of 8-Bromo-cAMP With Various Drugs on the S-I Outflow of Radioactivity
The cell-permeable cAMP analogue 8-bromo-cAMP (30, 100, and 300 ,umol/L), when added in increasing concentrations 12 minutes before S2 to S4, dose-dependently enhanced the S-I outflow of radioactivity to 108.4±6.8%, 126.8±7.0%, and 168.3±14.4% of the control value (n=5), respectively. The following results were obtained in experiments with two stimulations (S, and S2): A combination of the phosphodiesterase inhibitor IBMX (90 gttmol/L) and 8-bromo-cAMP (300 4tmol/L), which was added 12 minutes before S2, enhanced the S-I outflow of radioactivity to a slightly greater extent than 8-bromo-cAMP (300 ,umol/L) alone ( Fig 5) . A combination of 8-bromo-cAMP (300 ,gmol/L)/IBMX (90 ,umol/L) and isoproterenol (0.1 ,tmol/L), which were added together to the superfusion solution 12 minutes before S2, did not enhance S-I outflow of radioactivity to a greater extent than did 8-bromo-cAMP (300 ,umol/L)/ IBMX (90 gmol/L) alone (Fig 5) . In contrast, a combination of 8-bromo-cAMP (300 ,umol/L)/IBMX (90 ,umol/L) and Ang 11 (0.1 gmol/L) enhanced S-I outflow of radioactivity to a greater extent than did 8-bromo-cAMP (300 ,umol/L)/IBMX (90 ,umol/L) alone ( Fig 5) . (30 to 300 ,.mol/L) and none of the drug combinations had an effect on the spontaneous outflow of radioactivity (data not shown).
Discussion
Human right atrial appendages are densely innervated by the sympathetic nervous system26 and seem to contain large amounts of norepinephrine as measured spectrophotofluorometrically. 27 Comparable levels of norepinephrine were measured in the present study by highpressure liquid chromatography. For comparison, human kidney cortex contains six times less norepinephrine2' than does human right atrium. Slices of human right atrial appendages, when incubated with tritiated norepinephrine, accumulated and stored radioactivity. Moreover, they released radioactivity on electrical stimulation in a frequency-dependent manner. Pretreatment of the atria with 6-hydroxydopamine, which destroys sympathetic nerve endings,28 reduced the ability to accumulate radioactivity and abolished the S-I outflow of radioactivity. As in previous studies in other sympathetically innervated tissues' incubated with [3H]norepinephrine, the spontaneous outflow of radioactivity from the atria was composed mainly of 3H metabolites, whereas intact [3HInorepinephrine accounted almost entirely for the S-I outflow of radioactivity. The S-I outflow of radioactivity was dependent on extracellular calcium and could be blocked by tetrodotoxin. Thus, superfused atrial slices provide a reliable technique to study the modulation of norepinephrine release from human cardiac sympathetic nerves in vitro.
P-Adrenergic Receptor Activation and Norepinephrine Release
The nonselective /,land A32-adrenergic receptor agonist isoproterenol concentration-dependently enhanced S-I outflow of radioactivity. This facilitatory effect was abolished by the selective f32-adrenergic receptor antagonist ICI 118551 (0.1 ,umol/L).29 A 10 times lower concentration of ICI 118551 (0.01 ,/mol/L) shifted the concentration-response curve of isoproterenol to the right with an estimated pKB23 of 9.1. This pKB for ICI 118551 is almost identical to that obtained for ICI 118551 in guinea pig papillary muscle30 and fits with the inhibition constants of ICI 118551 determined for [l251]iodopindolol binding and adenylate cyclase activity. 31 In contrast, the selective 6,1-adrenergic receptor antagonist atenolol32at a concentration of 0.3 ,umol/L, and even at 30 /Lmol/L, did not shift the concentration-response that activation of prejunctional P32-adrenergic receptors enhances norepinephrine release from sympathetic nerves in human atria. It has been suggested that norepinephrine activates prejunctional ,B-adrenergic receptors to form a "positive-feedback loop" on its own release in the guinea pig atria.8 If prejunctional 83-adrenergic receptors were activated by endogenous norepinephrine, then ,B-adrenergic receptor antagonists should inhibit norepinephrine release. However, the possibility of such a positive-feedback loop seems to be unlikely in human atria, since both ICI 118551 and atenolol failed to alter S-I outflow of radioactivity. Ang II Receptor Activation and Norepinephrine Release Another facilitatory prejunctional mechanism is mediated via Ang II receptors.'-417 Accordingly, Ang II dose-dependently enhanced the S-I outflow of radioactivity from human atria, and the maximal facilitatory effect was reached at a concentration of 0.1 ,umol/L. Ang II in high concentrations blocks the uptake of norepinephrine in the rabbit heart,33 and a similar effect may be responsible for the enhanced S-I outflow of radioactivity in the present study. However, the uptakeblocking effect of Ang II occurs only at Ang II concentrations of 10 ,mol/L,33 far higher than used in the present study. Moreover, in the present experiments, extraneuronal and neuronal uptake of norepinephrine was already blocked by corticosterone and cocaine. Furthermore, the facilitatory effect of Ang II was inhibited by the peptide Ang II receptor antagonist saralasin34, 35 and EXP 3174, the in vitro active form of the recently developed nonpeptide Ang II receptor antagonist losartan. 35 Thus, the facilitatory effect of Ang II seems to be due to activation of prejunctional Ang II receptors. An inhibitory effect of losartan on prejunctional Ang II receptor-mediated facilitation of transmitter release has been previously reported for isolated artery preparations of the rat and dog.35 Saralasin is a peptide Ang II receptor antagonist with partial agonist activity at Ang II receptors.34,35 However, saralasin (1 ,umol/L) by itself did not enhance S-I outflow of radioactivity from human atrial slices preincubated with [3Hlnorepinephrine. This is in contrast to observations in the rat isolated kidney.36 EXP 3174 by itself also failed to alter the S-I outflow of radioactivity, which suggests that under the experimental conditions used endogenous Ang II does not activate prejunctional Ang II receptors to enhance norepinephrine release in superfused human atrial slices.
There are only a few and controversial reports about prejunctional facilitatory effects of Ang II in humans. In an early study by Mendelsohn et al,37 infusion of Ang II into resting normotensive subjects failed to increase norepinephrine plasma levels. However, a more recent study in healthy normotensive volunteers38 has demonstrated a prejunctional facilitatory effect of Ang II on sympathetic neurotransmission. In this particular study, the effect of Ang IT infused into the left brachial artery on the reduction in forearm blood flow induced by lower-body negative pressure was examined. Ang II by itself did not significantly alter forearm blood flow but enhanced the vasoconstrictor response to lower-body exogenous norepinephrine. Thus, it appears that only in situations involving an activated sympathetic nervous system (lower-body negative pressure) does a prejunctional effect of Ang II become detectable. Heart failure is a clinical condition with an activated sympathetic nervous and renin-angiotensin system. Therefore, one could speculate that beneficial effects of Ang II receptor-blocking drugs39 and ACE inhibitors in the treatment of heart failure may be partly due to the prevention of facilitatory effects of endogenous Ang II on sympathetic neurotransmission.
cAMP and Norepinephrine Release
The cell-permeable stable cAMP analogue 8-bromo-cAMP40 dose-dependently enhanced S-I outflow of radioactivity from human atria preincubated with [3H]norepinephrine but had no effect on the spontaneous outflow. This is in accord with findings of Cubeddu et al,4' who determined that cAMP is only involved in the nerve stimulation-induced release of norepinephrine but does not interact with the norepinephrine release process itself. A dose-dependent facilitatory effect of cell-permeable cAMP analogues has been previously observed in mouse atria42 and the human pulmonary artery.43 It has been suggested that the facilitatory effect of f3-adrenergic receptor activation on norepinephrine release is linked to stimulation of adenylate cyclase and, hence, an increased formation of cAMP. 44 In the present study, a combination of 8-bromo-cAMP and the nonselective phosphodiesterase inhibitor IBMX45 was used to test this hypothesis. If intraneuronal levels of 8-bromo-cAMP and endogenous cAMP were already maximally increased, then isoproterenol should not be able to enhance neurotransmitter release through a cAMP-dependent mechanism. And indeed, when the maximal facilitatory concentration of isoproterenol (0.1 gmol/L) and the combination 8-bromo-cAMP (300 ,mol/L)/IBMX (90 ,.mol/L) were added together, their facilitatory effects were not additive. This seems not to be an unspecific effect of 8-bromo-cAMP/IBMX on transmitter release, since Ang 11 (0.1 ,umol/L) and the combination 8-bromo-cAMP/IBMX enhanced the S-I outflow of radioactivity to a greater extent than did Ang II alone. Our data indicate that f82-adrenergic receptor-in contrast to Ang II receptor-mediated facilitation of norepinephrine release in human atria involves cAMP as a second messenger. Similar conclusions have been drawn in previous studies involving mouse atria,42 rabbit pulmonary artery,46 and rat renal cortex.4748 In conclusion, the amount of norepinephrine released per nerve impulse from sympathetic nerves in human atria is facilitated through activation of prejunctional 32-adrenergic receptors and Ang II receptors. The cell-permeable stable cAMP analogue 8-bromo-cAMP enhances norepinephrine release from human atria, and 132-adrenergic receptor but not Ang II receptor facilitation of norepinephrine release seems to be linked to an adenylate cyclase pathway.
